GlassScriptPhysician profile
Margaret M Juarez
NPI 1093707788
$6,969.96
in general payments reported to CMS, 2019-2025
23 companies · $821 in 2025
The $821 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,221 · 2020: $894 · 2021: $1,400 · 2022: $867 · 2023: $903 · 2024: $865 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511 · Education: $78.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.51 |
| Education | $78.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,905.39 | 2019-2025 | |
| Pfizer INC. | $436.24 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $364.88 | 2023-2025 | Myfembree |
| Shield Therapeutics INC | $332.51 | 2022-2025 | Accrufer |
| Mayne Pharma Commercial LLC | $297.74 | 2021-2025 | |
| Amag Pharmaceuticals, INC. | $193.52 | 2019 | |
| Myovant Sciences INC. | $178.47 | 2021-2022 | |
| Medtronic, INC. | $164.38 | 2023 | Ligasure |
| Astellas Pharma US INC | $163.33 | 2024 | Veozah |
| Allergan, INC. | $163.11 | 2019-2020 | |
| Millicent US INC | $144.30 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Exeltis, USA INC. | $121.31 | 2023-2025 | Slynd |
| Sage Therapeutics, LLC | $104.20 | 2024 | |
| Coopersurgical, INC. | $100.00 | 2020 | |
| Avion Pharmaceuticals | $68.01 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $45.54 | 2019-2025 | Thinprep 2000 Processor |
| Therapeuticsmd, INC. | $42.82 | 2021-2022 | |
| Lupin INC. | $39.90 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $35.21 | 2019 | |
| Scynexis, INC. | $27.25 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $22.97 | 2025 | |
| Duchesnay USA Incorporated | $18.88 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Juarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.